Results 171 to 180 of about 582,498 (279)

Synergistic Mn‐MOF Activation of Pistol Ribozymes for Cancer Immunotherapy

Advanced Science, EarlyView.
A Mn2+‐based metal–organic framework delivers a catalytic Pistol ribozyme for targeted PD‐L1 mRNA cleavage in tumor cells, with the released Mn2+ not only inducing immune activation in immune cells but also increasing the Pistol ribozyme catalytic activity.
Ming Zhao, Shan Qiao, Jie Bai, Jingjing Zhang, Zhiqin Xi, Zhenzhen Li, Xuelin Zhan, Ying Zhang, Xiaotong Yu, Yao Chen, Yijin Liu   +10 more
wiley   +1 more source

Dietary Polyphenols (Flavonoids) Derived from Plants for Use in Therapeutic Health: Antioxidant Performance, ROS, Molecular Mechanisms, and Bioavailability Limitations. [PDF]

Int J Mol Sci
Bas TG.
europepmc   +1 more source

Adipocyte‐Derived Exosomal miR‐5099 Mitigates M1 Macrophage Polarization and Adipose Inflammation via c‐Met/NF‐κB Axis to Improve Metabolic Health

Advanced Science, EarlyView.
Celastrol upregulates adipocyte‐derived exosomal miR‐5099, suppressing the macrophage c‐Met/NF‐κB axis to mitigate pro‐inflammatory M1 polarization and adipose inflammation. These miR‐5099‐enriched exosomes also act as endocrine signals targeting the liver, muscle, and adipocytes to significantly enhance systemic insulin sensitivity.
Ping Tang, Lixin Tai, Hongxia Xu, Dongliang Zhu, Jiajia Li, Hao Feng, Jinghui Cui, Shuhai Lin, Li‐jun Di, Li Wang   +9 more
wiley   +1 more source

Oral Bioavailability of Monoclonal Antibody. [PDF]

Pharmaceutics
Verma A, Wu S, Shah DK.
europepmc   +1 more source

Chaperone‐Mediated Autophagic Degradation of USP9X in Macrophages Exacerbates Postmyocardial Infarction Inflammation and Cardiac Dysfunction

Advanced Science, EarlyView.
This study demonstrates that inflammatory stimuli induce the acetylation‐triggered, chaperone‐mediated autophagic degradation of ubiquitin‐specific peptidase 9 X‐linked (USP9X) in macrophages. USP9X acts as a macrophage “inflammation switch” after myocardial infarction (MI). USP9X loss destabilizes tumor necrosis factor receptor‐associated factor (TRAF)
Biqing Wang, Xiangheng Cai, Mengqi Li, Xue Liu, Junhui Xue, Ye Liu, Ding Ai, Xinyang Hu   +7 more
wiley   +1 more source

Stability of Medications Administered via Enteral Feeding Tubes: A Systematic Review. [PDF]

Clin Transl Sci
Alodat L, Shahin W, Breik L, Allahham A.
europepmc   +1 more source

Targeting PRKCN, an Essential Driver Orchestrating mTOR‐IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma

Advanced Science, EarlyView.
Constitutive PRKCN expression is driven by super‐enhancers and modulated by NF‐κB signaling in multiple myeloma (MM). PRKCN activates mTORC1/2‐IRF4 signaling axis and favors tumor cell growth independently of its kinase activity. IRF4 reciprocally promotes PRKCN transcription, creating a feed‐forward loop.
Koukou Tang, Dongpeng Jiang, Peng Ke, Xiaosen Bian, Lili Zhang, Ying Zhang, Tingting Zhu, Weiwei Qu, Wenhui Qi, Yang Xu, Chengcheng Fu, Depei Wu, Jianhong Chu   +12 more
wiley   +1 more source

Clinical Pharmacology Perspective on Direct-To-Subcutaneous Dosing of T Cell Engagers in Oncology First-In-Human Studies. [PDF]

Clin Transl Sci
Qiao W, Shahraz A, Vishwanathan K, Sawant-Basak A.   +3 more
europepmc   +1 more source

Pro‐ATO/Allicin Liposomes for Dual‐Pathway Targeting of p53‐Mutant Tumors

Advanced Science, EarlyView.
Schematic illustration of the “pro‐ATO”/allicin liposomal strategy. Liposomal encapsulation improves the stability and bioavailability of both agents while masking allicin's odor. Upon release in the tumor microenvironment, ATO reactivates structural p53 mutants, and allicin inhibits ATR signaling while releasing H2S, collectively inducing synthetic ...
Xiaoling Xu, WeiYi Cheng, Menghang Yang, Li He, WeiYe Ren, JingQuan Chen, LiTing He, Dandan Bao, Zhihong Zhu, Lixin Wang, Qinghua Yao, Ji‐Gang Piao   +11 more
wiley   +1 more source

Absolute Bioavailability of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC): Systemic Pharmacokinetics of the CRC-PIPAC-II Trial. [PDF]

Ann Surg Oncol
van den Heuvel TBM, Rauwerdink P, Hulshof E, van de Vlasakker VCJ, Moes DJAR, Pluimakers G, Rovers KPB, Creemers GJ, Burger PJWA, Nienhuijs SW, Wiezer RJ, Lurvink RJ, Boerma D, De Hingh IHJT, Deenen MJ.   +14 more
europepmc   +1 more source